SurModics Inc

SurModics — Investor Presentation (April 2019)

31 slides from SurModics's investor presentation, Apr 9, 2019

  1. Slide 1: Surmodics April 2019 Investor Presentation

    Gary MaharajPresident and CEOTim ArensVice President of Finance and CFOAPRIL 2019 1

  2. Slide 2: Safe Harbor

    Safe Harbor Some of the statements made during this presentation may be considered forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations regarding our performance in the near- and long-term, including our revenue and earn

  3. Slide 3: Focused on product innovation

    Focused on product innovation VISION3 of the Top 10 InnovationsFocused on PAD and designed to be: safe, clinically effective & improve healthcare economics IMPACT TO PATIENTSGrowing incidence of peripheral artery disease (PAD) IMPACT TO INVESTORSInvesting to build long-term sustainable growth and pr

  4. Slide 4: Vision of Surmodics: top innovations in vascular medicine

    ) of the top10 © INJOVA r\ INNOVATIO in vascular medicine L by VISION of SURMODICS

  5. Slide 5: Desired outcomes

    DESIRED OUTCOMESGoal of improving clinical outcomes while reducing healthcare costs PATIENTS202 million patients worldwide living with Peripheral Artery Disease (PAD) 5

  6. Slide 6: Impact to patients

    Impact to patients Product innovations aimed at making significant improvements in patient outcomes and quality of life (QOL) PATIENTS DESIRED OUTCOMES Superficial Femoral Artery (SFA)> 500K procedures annuallyPain on ambulation – reduced QOL Reduction in reintervention ratesImproved QOL by reductio

  7. Slide 7: Whole product solutions strategy

    7 Our whole product solutions strategy is focused on creating innovative, differentiated product platforms that solve clinically meaningful problems in treating peripheral vascular disease Desired OutcomesImprove Clinical OutcomesReduce Healthcare Costs Initial PlatformsDrug Coated BalloonsSurVeil®

  8. Slide 8: SurVeil DCB 12-Month Data

    SurVeil® DCB 12-Month Data Uniform drug topcoatPaclitaxel + proprietary excipient2.0 µg/mm² drug load360°coating coverage 0.035” OTW PTA platform4–7 mm x 40–150 mm Shaft coatingSerene® hydrophilic coating Proprietary PhotoLink® basecoat “The ongoing positive results from this study demonstrate that

  9. Slide 9: Current debate on paclitaxel-coated devices to treat PAD

    CURRENT DEBATE ON PACLITAXEL-coated DEVICES TO TREAT PAD 9 RECAP OF RECENTS EVENTS JANUARY 17FDA CommunicationBenefits outweigh risks 2018 DECEMBER 8 Katsanos Meta-Analysispublished in JAHA SRDX DISCUSSIONS with FDA MARCH 2-3VIVA ForumIn-depth review JUNE (PROBABLE)FDA PanelMeeting 2019 DEC JAN FEB

  10. Slide 10: December 8: Katsanos meta-analysis

    December 8: Katsanos meta-analysis Meta-Analysis Limitations:No access to patient-level dataNo plausible mechanism of action notedQuestions regarding statistical model usedSelection bias due to lack of complete follow upLost to follow up and withdrawals are not accurately or completely accountedPTA

  11. Slide 11: March 15: FDA Communication to Health Care Providers

    March 15: FDA Communication to Health Care Providers FDA conducted a preliminary pooled analysis of long-term follow-up data (up to 5 years) of the pivotal premarket RCTs for paclitaxel-coated products and has identified a potentially concerning signal of increased long-term mortality (analysis is o

  12. Slide 12: FDA Recommendations to US Health Care Providers

    FDA Recommendations to US Health Care Providers (March 15 Letter) Continue diligent monitoring of patientsEvaluate and inform of potential risksConsider there may be an increased rate of long-term mortality with paclitaxel-coated devices when recommending treatment or consenting patientsDiscuss the

  13. Slide 13: What is a "Signal"

    WHAT IS A “SIGNAL” From the FDA: A Signal represents new information which:May arise from one or several sourcesMay suggest a new potentially causal association between a marketed medical device and an event or set of related eventsMay justify or require further evaluation and/or action by the Agenc

  14. Slide 14: FDA's communication with Surmodics

    FDA's communication with surmodics FDA RECOMMENDATION FOR TRANSCEND:Follow the device recommendations outlined in March 15 letterUpdate patient informed consent form (ICF)Have ongoing independent Data Safety Monitoring Board (DSMB) reviewTake measures to increase follow-up of patients SURMODICS IMPL

  15. Slide 15: TRANSCEND: SurVeil DCB Pivotal Trial

    TRANSCEND: SURVEIL® DCB PIVOTAL TRIAL PRINCIPAL INVESTIGATORSWilliam (Bill) Gray, MD, FACC, FSCAIClinical Advisor — Main Line Health, Inc., Wynnewood, PAKenneth Rosenfield, MD Chair Advisory Board — Interventional Cardiology, Mass. General HospitalMarianne Brodmann MD, PhD Clinical Advisor— Interven

  16. Slide 16: Strategic Agreement with Abbott

    Strategic Agreement with Abbott Demonstrates value of whole-product solutions strategyLeverages Surmodics’ leadership in drug-delivery technologies, design, development capabilities, and manufacturing capacityCombines with Abbott’s deep experience in vascular care products and worldwide strength in

  17. Slide 17: Terms of Agreement

    Terms of Agreement CAUTION: SurVeil® Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use. 17 Exclusive worldwide commercialization rights for SurVeil® drug-coated balloon (DCB) for superficial femoral artery (SFA)$25 million upfront paym

  18. Slide 18: DCB platform extension

    DCB platform extension Surmodics .014” PTA platform2 – 4 mm diameter20 – 220 mm lengths Uniform sirolimus drug coatingSirolimus + Proprietary Excipient360° uniform coating coverage Avess™ AV Fistula DCB* VISION Surmodics .035” PTA platform4 – 12 mm diameter40 – 80 mm lengths Uniform paclitaxel drug

  19. Slide 19: We Are Making Progress On Our Whole-Product Solutions Strategy

    JANUARY 510 (K) Clearance for Telemark™ Coronary / Peripheral Support Catheter We Are Making Progress On Our Whole-Product Solutions Strategy 19 Drug-Coated Balloons (DCB) 510 (K) / CE Mark 2017 2018 SEPTEMBER Global Clearance of .014” Low-Profile PTA Balloon Catheter APRIL FDA Clearance for .018” L

  20. Slide 20: Thrombectomy Platform Technology

    Thrombectomy Platform Technology Acquired innovative thrombectomy platform technology and IP from EmbolitechGame-changing technology designed for removal of organized thrombi and emboli, in an approximately $400M growing global marketSimple stand-alone intervention, eliminates need for capital equip

  21. Slide 21: Radial Access Platform Technology

    Radial Access Platform Technology Radial artery access offers many benefits relative to femoral artery access including reduced bleeding complications, early ambulation, reduced length of stay and costsRadial access is widely adopted in coronary procedures where devices have been developed to accomm

  22. Slide 22: Product Milestones

    Product Milestones* *We continue to assess the impact of the FDA communication on certain product milestonesCAUTION: SurVeil®, Avess™ and Sundance™ Drug-Coated Balloons are investigational devices. Limited by Federal (or United States) law to investigational use. IMPACT TO INVESTORS CY 2019 GOALS FY

  23. Slide 23: Pipeline Products and Financial Performance Targets

    PIPELINE PRODUCTSSurVeil® DCBSundance™ Below-the-knee DCBAvess™ AV DCBMultiple 510(k)’s Financial Performance Targets>10% revenue growth (achieved fiscal 2018)>30% EBITDA margin by 2021 23 The agreement with Abbott has a meaningful positive impact on our commitment to deliver the returns described a

  24. Slide 24: Management Team

    MANAGEMENT TEAM Gary R. MaharajPresident and Chief Executive Officer (2010) Timothy J. ArensVice President of Finance and Chief Financial Officer (2007) Joseph J. Stich Vice President and General Manager of In Vitro Diagnostics (2010) Thomas GreaneyChief Operating Officer of Medical Devices (2015) G

  25. Slide 25: Clinical & Scientific Advisors

    Clinical & scientific ADVISORS Ken Rosenfield, MD Chair Advisory Board — Interventional CardiologyMassachusetts General Hospital Gary Ansel, MD, FACC Clinical Advisor — Interventional CardiologyOhio Health Research Marianne Brodmann MD, PhD Clinical Advisor— Interventional CardiologyDivision of Angi

  26. Slide 26: Surmodics business segments

    Surmodicsbusiness segments For the three months ended December 31, 2018 BUSINESSSEGMENTREVENUE IVDBUSINESS22% MEDICAL DEVICES78% 26

  27. Slide 27: Surmodics Core Business

    Surmodics CORE BUSINESS vascular access sheath coronary guidewire peripheral clad guidewire coronary stent delivery catheter coronary balloon dilatation catheter peripheral balloon dilatation catheter diagnostic guide catheter vascular access and support catheter MEDICAL DEVICE COATINGS IN VITRO DIA

  28. Slide 28: Financial Performance

    FINANCIAL PERFORMANCE 28 *We continue to assess the impact of the FDA communication on our fiscal 2019 financial and long-term guidance

  29. Slide 29: Financials by Segment

    FINANCIALS BY SEGMENT MISSION: To improve the treatment and detection of diseaseStrong balance sheet and attractive cash flows to fund growth strategy$45.9 million of cash/investments as of December 31, 2018Operating cash flow of $34.1 million and adjusted EBITDA of $7.3 million in fiscal 2018 MEDIC

  30. Slide 30: 2019 Guidance

    2019 Guidance(1) 2019 Financial Guidance Long Term Objectives Total Revenue: $94 million to $97 million (includes $14-$15 million of SurVeil DCB revenue)(2) GAAP Loss per Share(3): $(0.22) to $(0.02)Non-GAAP Earnings per Share(3): $0.02 to $0.22 Continue consistent double digit top line revenue grow

  31. Slide 31: Investor Relations

    INVESTOR RELATIONSFor additional inquiries, please contact:Tim Arens • 952-500-7056 31

Surmodics — Investor Presentation (April 2019) on 6ix